45 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00053 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 6.2% inhibition at 10-6 M |
| dbacp00054 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 6.4% inhibition at 10-5 M |
| dbacp00055 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 8.2% inhibition at 10-4 M |
| dbacp00056 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 21.2% inhibition at 10-3 M |
| dbacp00057 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 7.5% inhibition at 10-6 M |
| dbacp00058 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 6.1% inhibition at 10-5 M |
| dbacp00059 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 3.1% inhibition at 10-4 M |
| dbacp00060 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 14.8% inhibition at 10-3 M |
| dbacp00061 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 3.9% inhibition at 10-5 M |
| dbacp00062 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 7.3% inhibition at 10-3 M |
| dbacp00063 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 4.9% inhibition at 10-6 M |
| dbacp00064 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 8.9% inhibition at 10-5 M |
| dbacp00065 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 3.4% inhibition at 10-4 M |
| dbacp00066 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 20.8% inhibition at 10-3 M |
| dbacp00067 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.5% inhibition at 10-6 M |
| dbacp00068 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 21.9% inhibition at 10-5 M |
| dbacp00069 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 11.8% inhibition at 10-4 M |
| dbacp00070 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 17.9% inhibition at 10-3 M |
| dbacp00071 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 3.7% inhibition at 10-6 M |
| dbacp00072 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 16.5% inhibition at 10-5 M |
| dbacp00073 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 8.4% inhibition at 10-4 M |
| dbacp00074 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 14.5% inhibition at 10-3 M |
| dbacp00075 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 1.1% inhibition at 10-5 M |
| dbacp00076 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 1.2% inhibition at 10-4 M |
| dbacp00077 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 17.8% inhibition at 10-3 M |
| dbacp00078 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 8.5% inhibition at 10-6 M |
| dbacp00079 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 4.9% inhibition at 10-5 M |
| dbacp00080 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 1.9% inhibition at 10-4 M |
| dbacp00081 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 16.2% inhibition at 10-3 M |
| dbacp00082 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 7.2% inhibition at 10-6 M |
| dbacp00083 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 17.1% inhibition at 10-5 M |
| dbacp00084 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 11.0% inhibition at 10-4 M |
| dbacp00085 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 20.5% inhibition at 10-3 M |
| dbacp00086 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 3.0% inhibition at 10-6 M |
| dbacp00087 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 4.7% inhibition at 10-5 M |
| dbacp00088 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 2.7% inhibition at 10-4 M |
| dbacp00089 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 7.3% inhibition at 10-3 M |
| dbacp00090 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 0.7% inhibition at 10-6 M |
| dbacp00091 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 8.3% inhibition at 10-5 M |
| dbacp00092 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 10.5% inhibition at 10-4 M |
| dbacp00093 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 21.8% inhibition at 10-3 M |
| dbacp00094 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.7% inhibition at 10-6 M |
| dbacp00095 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.0% inhibition at 10-5 M |
| dbacp00096 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 7.7% inhibition at 10-4 M |
| dbacp00097 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 18.7% inhibition at 10-3 M |